Aradigm Corp (ARDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aradigm Corp (ARDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH1294D
  • |
  • Pages: 32
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Aradigm Corp (Aradigm) is a specialty pharmaceutical company that develops and commercializes inhalation drugs for the prevention and treatment of severe respiratory diseases. The company's product pipeline includes Pulmaquin (ARD-3150) and Lipoquin (ARD-3100) for the treatment of non-cystic bronchiectasis (BE) and cystic fibrosis (CF); ARD-1100, liposomal ciprofloxacin for the treatment of inhalation tularemia, anthrax infections, Q fever and pneumonic plague and ARD-1600, for the prevention and treatment of respiratory and other diseases in tobacco smokers through smoking cessation. Its proprietary pulmonary drug delivery platform, AERx, is customized for the delivery of drugs to the target along with liposomal formulations. Aradigm is headquartered in Hayward, California, the US.

Aradigm Corp (ARDM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aradigm Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aradigm Corp, Medical Devices Deals, 2012 to YTD 2018 9

Aradigm Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aradigm Corp, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Grifols Enters Into Licensing Agreement With Aradigm 11

Ingeniatrics Enters Into Licensing Agreement With Aradigm For Flow Focusing And Flow Blurring Technology 13

Equity Offering 14

Aradigm Rasies USD6 Million in Private Placement Of Shares 14

Aradigm Files Registration Statement for Public offering of Shares for up to USD20 Million 15

Debt Offering 16

Aradigm Raises Funds through First Tranche Private Placement of 9% Notes Due 2021 16

Acquisition 17

Grifols Completes Acquisition Of 35% Stake In Aradigm For USD 26 Million 17

Aradigm Corp-Key Competitors 18

Aradigm Corp-Key Employees 19

Aradigm Corp-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

Financial Announcements 21

Aug 14, 2018: Aradigm announces second quarter 2018 financial results 21

May 15, 2018: Aradigm Reports First Quarter 2018 Financial Results 22

Mar 23, 2018: Aradigm Reports Fourth Quarter 2017 And Full Year Financial Results 23

Nov 02, 2017: Aradigm Announces Third Quarter 2017 Financial Results 25

Aug 10, 2017: Aradigm Announces Second Quarter 2017 Financial Results 26

May 15, 2017: Aradigm Announces First Quarter 2017 Financial Results 27

Mar 28, 2017: Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results 28

Corporate Communications 29

Jul 06, 2018: Aradigm Names Dr. Theresa Matkovits As Board Director 29

Feb 09, 2018: Aradigm Announces Personnel Changes 30

Oct 10, 2017: Aradigm Regains Compliance with NASDAQ Listing Requirements 31

Appendix 32

Methodology 32

About GlobalData 32

Contact Us 32

Disclaimer 32

List of Figures

Aradigm Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aradigm Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aradigm Corp, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Aradigm Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aradigm Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aradigm Corp, Deals By Therapy Area, 2012 to YTD 2018 8

Aradigm Corp, Medical Devices Deals, 2012 to YTD 2018 9

Aradigm Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Grifols Enters Into Licensing Agreement With Aradigm 11

Ingeniatrics Enters Into Licensing Agreement With Aradigm For Flow Focusing And Flow Blurring Technology 13

Aradigm Rasies USD6 Million in Private Placement Of Shares 14

Aradigm Files Registration Statement for Public offering of Shares for up to USD20 Million 15

Aradigm Raises Funds through First Tranche Private Placement of 9% Notes Due 2021 16

Grifols Completes Acquisition Of 35% Stake In Aradigm For USD 26 Million 17

Aradigm Corp, Key Competitors 18

Aradigm Corp, Key Employees 19

Aradigm Corp, Subsidiaries 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Aradigm Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17805
Site License
USD 500 INR 35610
Corporate User License
USD 750 INR 53415

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com